Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy

Hepatology

Volumn 56, Issue 5, 2012, Pages 1719-1729

  Lee, Young Mok ^a   Jun, Hyun Sik ^a   Pan, Chi Jiunn ^a   Lin, Su Ru ^a   Wilson, Lane H ^a   Mansfield, Brian C ^a,b   Chou, Janice Y ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b Foundation Fighting Blindness   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE 6 PHOSPHATASE ALPHA; INSULIN; LIVER ENZYME; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME METABOLISM; FATTY LIVER; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCOGEN STORAGE DISEASE TYPE 1; GLYCOGEN STORAGE DISEASE TYPE 1A; INSULIN BLOOD LEVEL; LIPID STORAGE; LIVER ADENOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT;

ADENOMA; ANIMALS; ANTIPORTERS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC THERAPY; GENETIC VECTORS; GLUCOSE TOLERANCE TEST; GLUCOSE-6-PHOSPHATASE; GLYCOGEN STORAGE DISEASE TYPE I; HOMEOSTASIS; INSULIN; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, KNOCKOUT; MONOSACCHARIDE TRANSPORT PROTEINS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 84868210119     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25717     Document Type: Article

References (27)

1. Chou JY, Jun HS, Mansfield BC. Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy. Nat Rev Endocrinol 2010; 6: 676-688.
2. Greene HL, Slonim AE, O'Neill JAJr, Burr IM. Continuous nocturnal intragastric feeding for management of type 1 glycogen-storage disease. N Engl J Med 1976; 294: 423-425.
3. Chen YT, Cornblath M, Sidbury JB. Cornstarch therapy in type I glycogen storage disease. N Engl J Med 1984; 310: 171-175.
4. Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 1997; 24: 276-279.
5. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002; 161( Suppl 1): S20-S34.
6. Franco LM, Krishnamurthy V, Bali D, Weinstein DA, Arn P, Clary B, et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis 2005; 28: 153-162.
7. Chou JY, Mansfield BC. Recombinant AAV-directed gene therapy for type I glycogen storage diseases. Expert Opin Biol Ther 2011; 11: 1011-1024.
8. Yiu WH, Lee YM, Peng WT, Pan C-J, Mead PA, Mansfield BC, et al. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy. Mol Ther 2010; 18: 1076-1084.
9. Carter PJ, Samulski RJ. Adeno-associated viral vectors as gene delivery vehicles. Int J Mol Med 2000; 6: 17-27.
10. Tenenbaum L, Lehtonen E, Monahan PE. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther 2003; 3: 545-565.
11. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007; 317: 477.
12. Lei K-J, Chen H, Pan C-J, Ward JM, Mosinger B, Lee EJ, et al. Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type 1a mouse. Nat Genet 1996; 13: 203-209.
13. Mutel E, Abdul-Wahed A, Ramamonjisoa N, Stefanutti A, Houberdon I, Cavassila S, et al. Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas. J Hepatol 2011; 54: 529-537.
14. Yoshizawa T, Hinoi E, Jung DY, Kajimura D, Ferron M, Seo J, et al. The transcription factor ATF4 regulates glucose metabolism in mice through its expression in osteoblasts. J Clin Invest 2009; 119: 2807-2817.
15. Bahary N, Leibel RL, Joseph L, Friedman JM. Molecular mapping of the mouse db mutation. Proc Natl Acad Sci U S A 1990; 87: 8642-8646.
16. Kim SY, Weinstein DA, Starost MF, Mansfield BC, Chou JY. Necrotic foci, elevated chemokines and infiltrating neutrophils in the liver of glycogen storage disease type Ia. J Hepatol 2008; 48: 479-485.
17. Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 2006; 32: 28-44.
18. Leavens KF, Birnbaum MJ. Insulin signaling to hepatic lipid metabolism in health and disease. Crit Rev Biochem Mol Biol 2011; 46: 200-215.
19. de Luca C, Kowalski TJ, Zhang Y, Elmquist JK, Lee C, Kilimann MW, et al. Complete rescue of obesity, diabetes, and infertility in db/db mice by neuron-specific LEPR-B transgenes. J Clin Invest 2005; 115: 3484-3493.
20. Massa ML, Gagliardino JJ, Francini F. Liver glucokinase: an overview on the regulatory mechanisms of its activity. IUBMB Life 2011; 63: 1-6.
21. Hanson RW, Reshef L. Glyceroneogenesis revisited. Biochimie 2003; 85: 1199-1205.
22. Hers HG. Mechanisms of blood glucose homeostasis. J Inherit Metab Dis 1990; 13: 395-410.
23. Wamelink MM, Struys EA, Jakobs C. The biochemistry, metabolism and inherited defects of the pentose phosphate pathway: a review. J Inherit Metab Dis 2008; 31: 703-717.
24. Arion WJ, Lange AJ, Ballas LM. Quantitative aspects of relationship between glucose 6-phosphate transport and hydrolysis for liver microsomal glucose-6-phosphatase system. Selective thermal inactivation of catalytic component in situ at acid pH. J Biol Chem 1976; 251: 6784-690.
25. Zingone A, Hiraiwa H, Pan C-J, Lin B, Chen H, Ward JM, et al. Correction of glycogen storage disease type 1a in a mouse model by gene therapy. J Biol Chem 2000; 275: 828-832.
26. Lockwood DH, Merimee TJ, Edgar PJ, Greene ML, Fujimoto WY, Seegmiller JE, et al. Insulin secretion in type I glycogen storage disease. Diabetes 1969; 18: 755-758.
27. Rhee EJ, Lee WY, Cho YK, Kim BI, Sung KC. Hyperinsulinemia and the development of nonalcoholic fatty liver disease in nondiabetic adults. Am J Med 2011; 124: 69-76.